These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 21160410)

  • 21. CSF quinolinic acid levels are determined by local HIV infection: cross-sectional analysis and modelling of dynamics following antiretroviral therapy.
    Valle M; Price RW; Nilsson A; Heyes M; Verotta D
    Brain; 2004 May; 127(Pt 5):1047-60. PubMed ID: 15013955
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [HIV infection, antiretroviral therapy, and endothelium].
    Hürlimann D; Weber R; Enseleit F; Lüscher TF
    Herz; 2005 Sep; 30(6):472-80. PubMed ID: 16170677
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quinolinic acid in cerebrospinal fluid and serum in HIV-1 infection: relationship to clinical and neurological status.
    Heyes MP; Brew BJ; Martin A; Price RW; Salazar AM; Sidtis JJ; Yergey JA; Mouradian MM; Sadler AE; Keilp J
    Ann Neurol; 1991 Feb; 29(2):202-9. PubMed ID: 1826418
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multivariate normative comparison, a novel method for more reliably detecting cognitive impairment in HIV infection.
    Su T; Schouten J; Geurtsen GJ; Wit FW; Stolte IG; Prins M; Portegies P; Caan MW; Reiss P; Majoie CB; Schmand BA;
    AIDS; 2015 Mar; 29(5):547-57. PubMed ID: 25587908
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Neurological manifestations of the HIV infection].
    Arendt G; Nolting T
    MMW Fortschr Med; 2005 Apr; 147 Spec No 1():75-7. PubMed ID: 16385884
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Variable benefit in neuropsychological function in HIV-infected HAART-treated patients.
    Cysique LA; Maruff P; Brew BJ
    Neurology; 2006 May; 66(9):1447-50. PubMed ID: 16682686
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The HIV Dementia Scale: predictive power in mild dementia and HAART.
    Bottiggi KA; Chang JJ; Schmitt FA; Avison MJ; Mootoor Y; Nath A; Berger JR
    J Neurol Sci; 2007 Sep; 260(1-2):11-5. PubMed ID: 17482212
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antiretroviral drug treatment of CNS HIV-1 infection.
    Yilmaz A; Price RW; Gisslén M
    J Antimicrob Chemother; 2012 Feb; 67(2):299-311. PubMed ID: 22160207
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Neurological manifestations of HIV-infection in the era of highly active antiretroviral therapy (HAART)].
    Arendt G
    Fortschr Neurol Psychiatr; 2005 Oct; 73(10):577-86. PubMed ID: 16217698
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Laboratory evaluations in HIV-1-associated cognitive/motor complex.
    Syndulko K; Singer EJ; Nogales-Gaete J; Conrad A; Schmid P; Tourtellotte WW
    Psychiatr Clin North Am; 1994 Mar; 17(1):91-123. PubMed ID: 8190671
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Neurological complications of HIV infection. Review: new diagnostic, therapeutic and prognostic aspects].
    Radziwill AJ; Kappos L; Battegay M; Steck AJ
    Schweiz Med Wochenschr; 2000 Apr; 130(13):457-70. PubMed ID: 10812641
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death.
    Holkmann Olsen C; Mocroft A; Kirk O; Vella S; Blaxhult A; Clumeck N; Fisher M; Katlama C; Phillips AN; Lundgren JD;
    HIV Med; 2007 Mar; 8(2):96-104. PubMed ID: 17352766
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HIV-related neurocognitive impairment--a review.
    Rackstraw S
    Psychol Health Med; 2011 Oct; 16(5):548-63. PubMed ID: 21745034
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The assessment of cognitive function in advanced HIV-1 infection and AIDS dementia complex using a new computerised cognitive test battery.
    Cysique LA; Maruff P; Darby D; Brew BJ
    Arch Clin Neuropsychol; 2006 Feb; 21(2):185-94. PubMed ID: 16343841
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of aging and survival in a large HIV-infected cohort on antiretroviral therapy.
    Bakanda C; Birungi J; Mwesigwa R; Ford N; Cooper CL; Au-Yeung C; Chan K; Nachega JB; Wood E; Hogg RS; Dybul M; Mills EJ
    AIDS; 2011 Mar; 25(5):701-5. PubMed ID: 21160412
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neurocognitive impairment and neuroCART.
    Wright E
    Curr Opin HIV AIDS; 2011 Jul; 6(4):303-8. PubMed ID: 21546833
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Antiretroviral treatment for HIV infection. Where we are and where we are going?].
    Sierra-Madero JG; Franco-San-Sebastián D
    Rev Invest Clin; 2004; 56(2):222-31. PubMed ID: 15377075
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Dementia complex due to HIV disease and aging].
    Moulignier A
    Psychol Neuropsychiatr Vieil; 2007 Sep; 5(3):193-207. PubMed ID: 17872328
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antiretroviral nephrotoxicities.
    Atta MG; Deray G; Lucas GM
    Semin Nephrol; 2008 Nov; 28(6):563-75. PubMed ID: 19013327
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.